Background:

CH7057288 is a potent and selective TRK inhibitor.

CH7057288 induces regression of intracranial tumors and greatly improves event-free survival in an intracranial implantation model mimicking brain metastasis. CH7057288 can be a promising therapeutic agent for TRK fusion-positive cancer. TRK receptor tyrosine kinases are expressed as fusion proteins encoded by various fusion genes across a wide variety of cancer types, including lung and colorectal cancer[1].

[1]. Hiroshi Tanaka, et al. Abstract 4179: Potent and selective TRK inhibitor CH7057288. AACR Annual Meeting 2017; April 1-5, 2017.